The efficacy and safety of FGF19-targeted therapies, administered alone or in combination, ought to be evaluated in clinical trials, specifically in rare tumors including hepatoblastoma, DFSP GBM, and RMS. This evidence concerns the gene FGF19 and glioblastoma.